Jonathan  Young net worth and biography

Jonathan Young Biography and Net Worth

Jonathan Young is Executive Vice President and COO of Akero Therapeutics, a company he co-founded to advance promising new therapeutics to treat metabolic disease. Jonathan joined Apple Tree Partners as a Venture Partner in 2016, and has more than 15 years of experience in drug development, biotech law, and public policy. Prior to joining ATP, Jonathan served as General Counsel and Vice President of Policy/Advocacy at Braeburn Pharmaceuticals, Inc., an ATP portfolio company. He previously worked as Partner and General Counsel of FoxKiser, a Washington, D.C. law firm specializing in regulatory approval and life cycle management for pharmaceutical and biotechnology companies.

Jonathan was appointed by President Barack Obama, and confirmed by the US Senate, to serve as Chairman of the National Council on Disability, an independent federal agency advising the President and Congress on disability policy, and previously coordinated White House disability policy for President Bill Clinton. Jonathan earned a PhD in American history from the University of North Carolina at Chapel Hill, and a JD from Yale Law School.

What is Jonathan Young's net worth?

The estimated net worth of Jonathan Young is at least $5.74 million as of April 1st, 2024. Dr. Young owns 263,306 shares of Akero Therapeutics stock worth more than $5,737,438 as of April 16th. This net worth estimate does not reflect any other assets that Dr. Young may own. Additionally, Dr. Young receives a salary of $763,300.00 as COO at Akero Therapeutics. Learn More about Jonathan Young's net worth.

How old is Jonathan Young?

Dr. Young is currently 54 years old. There are 6 older executives and no younger executives at Akero Therapeutics. The oldest executive at Akero Therapeutics is Dr. Timothy Rolph, Co-Founder & Chief Scientific Officer, who is 70 years old. Learn More on Jonathan Young's age.

What is Jonathan Young's salary?

As the COO of Akero Therapeutics, Inc., Dr. Young earns $763,300.00 per year. There are 3 executives that earn more than Dr. Young. The highest earning executive at Akero Therapeutics is Dr. Andrew Cheng M.D., Ph.D., President, CEO & Director, who commands a salary of $1,220,000.00 per year. Learn More on Jonathan Young's salary.

How do I contact Jonathan Young?

The corporate mailing address for Dr. Young and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at [email protected]. Learn More on Jonathan Young's contact information.

Has Jonathan Young been buying or selling shares of Akero Therapeutics?

Within the last three months, Jonathan Young has sold $121,900.00 in shares of Akero Therapeutics stock. Most recently, Jonathan Young sold 5,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $24.38, for a transaction totalling $121,900.00. Following the completion of the sale, the chief operating officer now directly owns 263,306 shares of the company's stock, valued at $6,419,400.28. Learn More on Jonathan Young's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, Akero Therapeutics insiders bought shares 6 times. They purchased a total of 350,000 shares worth more than $11,281,700.00. During the last twelve months, insiders at the sold shares 32 times. They sold a total of 450,037 shares worth more than $19,092,428.88. The most recent insider tranaction occured on April, 1st when COO Jonathan Young sold 5,000 shares worth more than $121,900.00. Insiders at Akero Therapeutics own 9.7% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 4/1/2024.

Jonathan Young Insider Trading History at Akero Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/1/2024Sell5,000$24.38$121,900.00263,306View SEC Filing Icon  
12/27/2023Sell5,414$24.00$129,936.00185,131View SEC Filing Icon  
12/14/2023Sell543$20.76$11,272.68185,131View SEC Filing Icon  
11/17/2023Sell30,000$14.68$440,400.00153,177View SEC Filing Icon  
10/2/2023Sell490$51.10$25,039.00183,177View SEC Filing Icon  
9/13/2023Sell562$50.34$28,291.08183,177View SEC Filing Icon  
6/13/2023Sell538$55.16$29,676.08183,739View SEC Filing Icon  
1/3/2023Sell8,777$54.64$479,575.28184,911View SEC Filing Icon  
12/27/2022Sell12,500$49.57$619,625.00182,449View SEC Filing Icon  
10/25/2022Sell12,500$44.72$559,000.00163,254View SEC Filing Icon  
11/3/2021Sell18,780$24.27$455,790.60View SEC Filing Icon  
4/1/2021Sell3,055$28.75$87,831.25170,120View SEC Filing Icon  
3/1/2021Sell3,055$30.48$93,116.40173,375View SEC Filing Icon  
1/8/2021Sell10,000$28.12$281,200.00189,285View SEC Filing Icon  
1/4/2021Sell3,060$25.29$77,387.40181,885View SEC Filing Icon  
See Full Table

Jonathan Young Buying and Selling Activity at Akero Therapeutics

This chart shows Jonathan Young's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $21.79
Low: $21.38
High: $22.04

50 Day Range

MA: $24.56
Low: $17.76
High: $31.18

2 Week Range

Now: $21.79
Low: $11.25
High: $58.38


940,162 shs

Average Volume

1,295,313 shs

Market Capitalization

$1.23 billion

P/E Ratio


Dividend Yield